Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 612

1.

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.

Shimokawa M, Nosaki K, Seto T, Ohashi K, Morise M, Horinouchi H, Sakakibara J, Murakami H, Yano S, Satouchi M, Matsumoto S, Goto K, Yoh K.

Trials. 2020 Mar 30;21(1):298. doi: 10.1186/s13063-020-4221-7.

2.

Cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan.

Matsubara N, Suzuki K, Kazama H, Tsukube S, Seto T, Matsuyama H.

J Geriatr Oncol. 2020 Mar 17. pii: S1879-4068(19)30502-8. doi: 10.1016/j.jgo.2020.02.014. [Epub ahead of print]

3.

Insights in Public Health: Outpatient Care Gaps for Patients Hospitalized with Ambulatory Care Sensitive Conditions in Hawai'i: Beyond Access and Continuity of Care.

Sentell TL, Seto TB, Quensell ML, Malabed JM, Guo M, Vawer MD, Braun KL, Taira DA, Sentell TL, Nakata MN.

Hawaii J Health Soc Welf. 2020 Mar 1;79(3):91-97.

4.

Skeletal muscle quality affects patient outcomes in acute type A aortic dissection.

Gomibuchi T, Seto T, Chino S, Mikoshiba T, Komatsu M, Tanaka H, Ichimura H, Yamamoto T, Ohashi N, Fuke M, Wada Y, Okada K.

Interact Cardiovasc Thorac Surg. 2020 Mar 10. pii: ivaa008. doi: 10.1093/icvts/ivaa008. [Epub ahead of print]

PMID:
32163575
5.

Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.

Shimokawa M, Nosaki K, Seto T, Ohashi K, Morise M, Fujiwara Y, Sakakibara J, Murakami H, Yano S, Satouchi M, Matsumoto S, Goto K, Yoh K.

Ann Oncol. 2019 Apr;30 Suppl 2:ii66. doi: 10.1093/annonc/mdz063.079. No abstract available.

6.

Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2.

Barlesi F, Drilon A, De Braud F, Cho BC, Ahn MJ, Siena S, Krebs MG, Lin CC, John T, Tan DSW, Seto T, Dziadziuszko R, Arkenau HT, Rolfo C, Wolf J, Ye C, Riehl T, Eng S, Doebele RC.

Ann Oncol. 2019 Apr;30 Suppl 2:ii48-ii49. doi: 10.1093/annonc/mdz063.007. No abstract available.

7.

Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001.

Paz-Ares L, Doebele RC, Farago AF, Liu SV, Chawla SP, Tosi D, Blakely CM, Krauss JC, Sigal D, Bazhenova L, John T, Besse B, Wolf J, Seto T, Chow-Maneval E, Ye C, Simmons B, Demetri GD.

Ann Oncol. 2019 Apr;30 Suppl 2:ii48-ii49. doi: 10.1093/annonc/mdz063.011. No abstract available.

8.

Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma.

Takamori S, Seto T, Jinnouchi M, Oba T, Yamaguchi M, Takenoyama M.

Ther Clin Risk Manag. 2020 Jan 17;16:17-20. doi: 10.2147/TCRM.S229860. eCollection 2020.

9.

S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501.

Fukuda M, Funaki S, Yamazaki T, Sato S, Mukae H, Takenoyama M, Fukuoka J, Nabeshima K, Tateyama H, Ashizawa K, Hara M, Seto T, Okumura M, Sugio K.

Thorac Cancer. 2020 Mar;11(3):693-696. doi: 10.1111/1759-7714.13319. Epub 2020 Feb 5. Review.

10.

Two cases with giant cell tumor arising from the sternum: Diagnosis and options for treatment.

Muramatsu K, Tani Y, Seto T, Roces G, Yamamoto M, Ichihara Y, Sakai T.

J Orthop Sci. 2020 Jan 28. pii: S0949-2658(19)30335-5. doi: 10.1016/j.jos.2019.10.014. [Epub ahead of print] No abstract available.

PMID:
32001081
11.

Spatial distribution of macular pigment estimated by autofluorescence imaging in elderly Japanese individuals.

Obana A, Gohto Y, Sasano H, Gellermann W, Sharifzadeh M, Seto T, Bernstein PS.

Jpn J Ophthalmol. 2020 Mar;64(2):160-170. doi: 10.1007/s10384-020-00716-5. Epub 2020 Jan 27.

PMID:
31989400
12.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

Park K, Vansteenkiste J, Lee KH, Pentheroudakis G, Zhou C, Prabhash K, Seto T, Voon PJ, Tan DSW, Yang JCH, Wang J, Babu KG, Nakayama Y, Alip A, Chua KLM, Cheng JC, Senan S, Ahn YC, Kim TY, Ahn HK, Peters S, Yoshino T, Douillard JY.

Ann Oncol. 2020 Feb;31(2):191-201. doi: 10.1016/j.annonc.2019.10.026. Epub 2019 Dec 20.

PMID:
31959336
13.

Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.

Niho S, Yoshida T, Akimoto T, Sakamaki K, Ono A, Seto T, Nishio M, Yamamoto N, Hida T, Okamoto H, Kurata T, Satouchi M, Goto K, Yamanaka T, Ohe Y.

Lung Cancer. 2020 Mar;141:64-71. doi: 10.1016/j.lungcan.2020.01.008. Epub 2020 Jan 10.

PMID:
31955002
14.

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.

Tan DS, Leighl NB, Riely GJ, Yang JC, Sequist LV, Wolf J, Seto T, Felip E, Aix SP, Jonnaert M, Pan C, Tan EY, Ko J, Moody SE, Kim DW.

Lancet Respir Med. 2020 Jan 15. pii: S2213-2600(19)30267-X. doi: 10.1016/S2213-2600(19)30267-X. [Epub ahead of print]

PMID:
31954624
15.

Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503.

Kubota K, Kunitoh H, Seto T, Shimada N, Tsuboi M, Ohhira T, Okamoto H, Masuda N, Maruyama R, Shibuya M, Watanabe K.

Lung Cancer. 2020 Mar;141:32-36. doi: 10.1016/j.lungcan.2019.11.009. Epub 2019 Nov 29.

PMID:
31931444
16.

Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3.

Yoshioka H, Kato T, Okamoto I, Tanaka H, Hida T, Seto T, Kiura K, Tian Y, Azuma H, Yamamoto N.

Future Oncol. 2020 Feb;16(4):49-60. doi: 10.2217/fon-2019-0659. Epub 2020 Jan 10.

17.

Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).

Seto T, Azuma K, Yamanaka T, Sugawara S, Yoshioka H, Wakuda K, Atagi S, Iwamoto Y, Hayashi H, Okamoto I, Saka H, Mitsuoka S, Fujimoto D, Nishino K, Horiike A, Daga H, Sone T, Yamamoto N, Nakagawa K, Nakanishi Y.

J Clin Oncol. 2020 Mar 10;38(8):793-803. doi: 10.1200/JCO.19.01494. Epub 2019 Dec 27.

PMID:
31880966
18.

Acute Generalized Exanthematous Pustulosis Caused by the Combination of Pembrolizumab Plus Chemotherapy in a Patient With Squamous-Cell Carcinoma.

Matsubara T, Uchi H, Haratake N, Takamori S, Toyozawa R, Miura N, Yamaguchi M, Seto T, Takenoyama M.

Clin Lung Cancer. 2020 Mar;21(2):e54-e56. doi: 10.1016/j.cllc.2019.11.009. Epub 2019 Nov 20. No abstract available.

PMID:
31874730
19.

Cerclage Wiring Fixation for the Treatment of Long Oblique Fractures of the Distal Clavicle: A Report of 2 Cases.

Matsumura N, Takada Y, Seto T, Suzuki T, Iwamoto T, Sato K.

JBJS Case Connect. 2019 Dec;9(4):e0085. doi: 10.2106/JBJS.CC.19.00085.

PMID:
31850913
20.

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators.

Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11. Erratum in: Lancet Oncol. 2020 Feb;21(2):e70.

PMID:
31838015
21.

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators.

Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. Erratum in: Lancet Oncol. 2020 Feb;21(2):e70.

PMID:
31838007
22.

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.

Nakagawa K, Hida T, Nokihara H, Morise M, Azuma K, Kim YH, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Koyama R, Mitsudomi T, Yamamoto N, Asakawa T, Hayashi M, Hasegawa W, Tamura T.

Lung Cancer. 2020 Jan;139:195-199. doi: 10.1016/j.lungcan.2019.11.025. Epub 2019 Nov 28.

PMID:
31812890
23.

Phase II study of vinorelbine plus carboplatin with concurrent radiotherapy in elderly patients with non-small cell lung cancer.

Yamaguchi M, Hirata H, Ebi N, Araki J, Seto T, Maruyama R, Akamine S, Inoue Y, Semba H, Sasaki J, Okamoto T.

Jpn J Clin Oncol. 2020 Mar 9;50(3):318-324. doi: 10.1093/jjco/hyz179.

PMID:
31804689
24.

Autophagy in the Central Nervous System and Effects of Chloroquine in Mucopolysaccharidosis Type II Mice.

Maeda M, Seto T, Kadono C, Morimoto H, Kida S, Suga M, Nakamura M, Kataoka Y, Hamazaki T, Shintaku H.

Int J Mol Sci. 2019 Nov 20;20(23). pii: E5829. doi: 10.3390/ijms20235829.

25.

Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab.

Ohba T, Takamori S, Toyozawa R, Nosaki K, Umeyama Y, Haratake N, Miura N, Yamaguchi M, Taguchi K, Seto T, Shimokawa M, Takenoyama M.

J Thorac Dis. 2019 Sep;11(9):3757-3768. doi: 10.21037/jtd.2019.09.29.

26.

Narrowing down the region responsible for 1q23.3q24.1 microdeletion by identifying the smallest deletion.

Hoshina T, Seto T, Shimono T, Sakamoto H, Okuyama T, Hamazaki T, Yamamoto T.

Hum Genome Var. 2019 Oct 18;6:47. doi: 10.1038/s41439-019-0079-1. eCollection 2019.

27.

Successful treatment of severe acute respiratory distress syndrome due to Group A streptococcus induced toxic shock syndrome in the third trimester of pregnancy-effectiveness of venoarterial extracorporeal membrane oxygenation: A case report.

Ichikawa D, Jwa SC, Seto T, Tarumoto N, Haga Y, Kohno K, Okagaki R, Ishihara O, Kamei Y.

J Obstet Gynaecol Res. 2020 Jan;46(1):167-172. doi: 10.1111/jog.14138. Epub 2019 Oct 8.

PMID:
31595595
28.

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators.

Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4.

PMID:
31591063
29.

Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.

Takeda M, Ohe Y, Horinouchi H, Hida T, Shimizu J, Seto T, Nosaki K, Kishimoto T, Miyashita I, Yamada M, Kaneko Y, Morimoto C, Nakagawa K.

Lung Cancer. 2019 Nov;137:64-70. doi: 10.1016/j.lungcan.2019.09.010. Epub 2019 Sep 16.

30.

Glomerular solidification is associated with nephritis-related clinical parameters in IgA nephropathy.

Inoue T, Luo Y, Seto T, Suzuki H, Okada H.

Ren Fail. 2019 Nov;41(1):893-898. doi: 10.1080/0886022X.2019.1665545.

31.

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer.

Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T.

Ann Oncol. 2019 Dec 1;30(12):1978-1984. doi: 10.1093/annonc/mdz399.

PMID:
31553438
32.

T Cell-Specific Adaptor Protein Regulates Mitochondrial Function and CD4+ T Regulatory Cell Activity In Vivo following Transplantation.

Wedel J, Stack MP, Seto T, Sheehan MM, Flynn EA, Stillman IE, Kong SW, Liu K, Briscoe DM.

J Immunol. 2019 Oct 15;203(8):2328-2338. doi: 10.4049/jimmunol.1801604. Epub 2019 Sep 20.

PMID:
31541025
33.

Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017.

Nakahara Y, Hosomi Y, Shibuya M, Mitsufuji H, Katagiri M, Naoki K, Soejima K, Nogami N, Nagase S, Nishikawa M, Minato K, Takiguchi Y, Seki N, Yamada K, Seto T, Okamoto H.

Mol Clin Oncol. 2019 Oct;11(4):349-353. doi: 10.3892/mco.2019.1903. Epub 2019 Jul 23.

34.

The effects of toe grip training on physical performance and cognitive function of nursing home residents.

Tsuyuguchi R, Kurose S, Seto T, Takao N, Fujii A, Tsutsumi H, Otsuki S, Kimura Y.

J Physiol Anthropol. 2019 Aug 28;38(1):11. doi: 10.1186/s40101-019-0202-5.

35.

Deuterium oxide protects against myocardial injury induced by ischemia and reperfusion in rats.

Ishikawa Y, Kitagawa H, Sawada T, Seto T, Takahashi K, Yamazaki T.

Scand Cardiovasc J. 2019 Dec;53(6):329-336. doi: 10.1080/14017431.2019.1657939. Epub 2019 Aug 28.

PMID:
31455109
36.

Genomic landscape of ductal carcinoma in situ and association with progression.

Lin CY, Vennam S, Purington N, Lin E, Varma S, Han S, Desa M, Seto T, Wang NJ, Stehr H, Troxell ML, Kurian AW, West RB.

Breast Cancer Res Treat. 2019 Nov;178(2):307-316. doi: 10.1007/s10549-019-05401-x. Epub 2019 Aug 17.

PMID:
31420779
37.

Association between bovine leukemia virus proviral load and severity of clinical mastitis.

Watanabe A, Murakami H, Kakinuma S, Murao K, Ohmae K, Isobe N, Akamatsu H, Seto T, Hashimura S, Konda K, Shinozuka Y, Kawai K.

J Vet Med Sci. 2019 Oct 18;81(10):1431-1437. doi: 10.1292/jvms.19-0285. Epub 2019 Aug 12.

38.

Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study.

Suzuki K, Matsubara N, Kazama H, Seto T, Tsukube S, Matsuyama H.

Jpn J Clin Oncol. 2019 Dec 27;49(12):1157-1163. doi: 10.1093/jjco/hyz108.

39.

Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients.

Haratake N, Seto T, Takamori S, Toyozawa R, Nosaki K, Miura N, Ohba T, Toyokawa G, Taguchi K, Yamaguchi M, Shimokawa M, Takenoyama M.

Thorac Cancer. 2019 Sep;10(9):1779-1787. doi: 10.1111/1759-7714.13143. Epub 2019 Jul 23.

40.

PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes.

Magnani CJ, Li K, Seto T, McDonald KM, Blayney DW, Brooks JD, Hernandez-Boussard T.

J Natl Compr Canc Netw. 2019 Jul 1;17(7):795-803. doi: 10.6004/jnccn.2018.7274.

PMID:
31319390
41.

Adding Social Determinants in the Electronic Health Record in Clinical Care in Hawai'i: Supporting Community-Clinical Linkages in Patient Care.

Trinacty CM, LaWall E, Ashton M, Taira D, Seto TB, Sentell T.

Hawaii J Med Public Health. 2019 Jun;78(6 Suppl 1):46-51.

42.

Skin Carotenoid Index in a large Japanese population sample.

Obana A, Gohto Y, Gellermann W, Ermakov IV, Sasano H, Seto T, Bernstein PS.

Sci Rep. 2019 Jun 27;9(1):9318. doi: 10.1038/s41598-019-45751-6.

43.

Genomic backgrounds of Japanese patients with undiagnosed neurodevelopmental disorders.

Yamamoto T, Imaizumi T, Yamamoto-Shimojima K, Lu Y, Yanagishita T, Shimada S, Chong PF, Kira R, Ueda R, Ishiyama A, Takeshita E, Momosaki K, Ozasa S, Akiyama T, Kobayashi K, Oomatsu H, Kitahara H, Yamaguchi T, Imai K, Kurahashi H, Okumura A, Oguni H, Seto T, Okamoto N.

Brain Dev. 2019 Oct;41(9):776-782. doi: 10.1016/j.braindev.2019.05.007. Epub 2019 Jun 4.

PMID:
31171384
44.

The Influence of Clinical T Factor on Predicting Pathologic N Factor in Resected Lung Cancer.

Shimamatsu S, Takenoyama M, Shimokawa M, Takada K, Edagawa M, Toyozawa R, Nosaki K, Oba T, Tagawa T, Yamaguchi M, Taguchi K, Seto T.

Ann Thorac Surg. 2019 Oct;108(4):1080-1086. doi: 10.1016/j.athoracsur.2019.04.026. Epub 2019 May 16.

PMID:
31103386
45.

Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).

Fukuda M, Kitazaki T, Ogawara D, Ichiki M, Mukae H, Maruyama R, Nakagaki N, Shimada M, Ikeda T, Kishimoto J, Harada T, Seto T, Ebi N, Takayama K, Okamoto I, Ichinose Y, Sugio K.

Lung Cancer. 2019 Jun;132:1-8. doi: 10.1016/j.lungcan.2019.01.008. Epub 2019 Apr 5.

PMID:
31097081
46.

The Association of Black Cardiologists (ABC) Cardiovascular Implementation Study (CVIS): A Research Registry Integrating Social Determinants to Support Care for Underserved Patients.

Ofili EO, Schanberg LE, Hutchinson B, Sogade F, Fergus I, Duncan P, Hargrove J, Artis A, Onyekwere O, Batchelor W, Williams M, Oduwole A, Onwuanyi A, Ojutalayo F, Cross JA, Seto TB, Okafor H, Pemu P, Immergluck L, Foreman M, Mensah EA, Quarshie A, Mubasher M, Baker A, Ngare A, Dent A, Malouhi M, Tchounwou P, Lee J, Hayes T, Abdelrahim M, Sarpong D, Fernandez-Repollet E, Sodeke SO, Hernandez A, Thomas K, Dennos A, Smith D, Gbadebo D, Ajuluchikwu J, Kong BW, McCollough C, Weiler SR, Natter MD, Mandl KD, Murphy S.

Int J Environ Res Public Health. 2019 May 10;16(9). pii: E1631. doi: 10.3390/ijerph16091631.

47.

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.

Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N.

Int J Clin Oncol. 2019 Jul;24(7):731-770. doi: 10.1007/s10147-019-01431-z. Epub 2019 May 2.

48.

Weakly supervised natural language processing for assessing patient-centered outcome following prostate cancer treatment.

Banerjee I, Li K, Seneviratne M, Ferrari M, Seto T, Brooks JD, Rubin DL, Hernandez-Boussard T.

JAMIA Open. 2019 Apr;2(1):150-159. doi: 10.1093/jamiaopen/ooy057. Epub 2019 Jan 4.

49.

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study.

Katsuya Y, Horinouchi H, Seto T, Umemura S, Hosomi Y, Satouchi M, Nishio M, Kozuki T, Hida T, Sukigara T, Nakamura K, Kuchiba A, Ohe Y.

Eur J Cancer. 2019 May;113:78-86. doi: 10.1016/j.ejca.2019.03.012. Epub 2019 Apr 13.

50.

Germline BRCA1 Deletion as Driver Mutation for Metastatic Urachal Adenocarcinoma in Patient Who Achieved Complete Response to Rucaparib.

Seto T, Pujare D, Song MN, Lee J, Huber R, Sam D, Pan M.

J Oncol Pract. 2019 May;15(5):293-295. doi: 10.1200/JOP.18.00708. Epub 2019 Apr 2. No abstract available.

PMID:
30939057

Supplemental Content

Support Center